🇺🇸 FDA
Pipeline program

SLN124

SLN124-002

Phase 1 small_molecule completed

Quick answer

SLN124 for Non-transfusion-dependent Thalassemia is a Phase 1 program (small_molecule) at Silence Therapeutics plc with 1 ClinicalTrials.gov record(s).

Program details

Company
Silence Therapeutics plc
Indication
Non-transfusion-dependent Thalassemia
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials